This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Mylan Launches Innovative Portfolio Of Antiretroviral Products For Treatment Of HIV/AIDS In South Africa

Stocks in this article: MYL

JOHANNESBURG and PITTSBURGH, Feb. 23, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL), one of the world's leading generic and specialty pharmaceutical companies, today announced that its subsidiary in South Africa, Mylan (Proprietary) Limited, has launched a comprehensive portfolio of antiretroviral (ARV) products. South Africa has the world's largest HIV/AIDS population, with approximately 5.6 million 1 people living with the disease and an estimated 1.7 million 2 people receiving treatment.

Mylan's South African ARV portfolio initially will consist of 11 first- and second-line adult and pediatric regimens. Included are several innovative products, such as fixed-dose combinations, single blister "co-packs," heat-stable products and novel pediatric formulations that have been approved by the U.S. Food and Drug Administration (FDA) and the World Health Organization (WHO).

Mylan CEO Heather Bresch commented, "Mylan's mission is to provide the world's 7 billion people with access to high quality medicine. Recently, Mylan was awarded a 19% share of the ARV tender conducted by the South African government and we already have begun to deliver on this commitment. Building on this, today we are pleased to launch a broad and innovative ARV portfolio for the private sector. We believe that Mylan can set a new standard in the treatment of HIV/AIDS in South Africa by providing health care providers and those living with the disease access to high quality, affordable medicines."

Paul Miller, managing director and vice president of Mylan's South African business noted, "Mylan is an established leader in ARVs, with a global portfolio of 43 high quality ARVs, and the company has played a significant role in reducing the cost of these important therapies. The launch of Mylan's ARV portfolio in South Africa builds on our existing commercial presence in the country and is consistent with the company's commitment to addressing unmet needs with quality products. Mylan's ARV medicines are produced according to current Good Manufacturing Practices at facilities that have been inspected by leading regulatory authorities, including the South African Medicines Control Council, FDA and WHO. These quality standards are paramount everywhere that Mylan operates, including in South Africa."

Mylan has been a leading global player in the ARV arena for more than a decade. In 2002, Mylan Laboratories Limited (formerly Matrix Laboratories Limited) began providing reliable supplies of ARV active pharmaceutical ingredients to generic drug makers. In 2007, the company began offering finished dosage forms and launched a line of pediatric ARVs. Today, Mylan is widely respected for the quality, dependability and affordability of its ARVs. Mylan supplies ARVs to more than 120 countries around the world and nearly 40% of HIV/AIDS patients receiving treatment in developing countries depend on one of the company's ARV products.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,974.31 -31.44 -0.18%
S&P 500 0.00 -2.75 -0.14%
NASDAQ 4,549.2260 -15.0680 -0.33%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs